This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the new three-year results for Eli Lilly’s EBGLYSS, an interleukin-13 (IL-13) inhibitor, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in patients with moderate-to-severe atopic dermatitis (eczema).
Ticker(s): LLYWho's the expert?
Institution: Bryn Mawr Medical
- Dermatologist and clinical faculty at the University of Pennsylvania
- Treats 100+ adolescent patients with moderate to severe plaque psoriasis annually
- Very familiar with the recent clinical data for icotrokinra, including its PASI 100 results and oral dosing profile
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
